Annual report for the Association for Accessible Medicines recapping 2013. View press release to learn more about the successful rebrand.
2013 was a year of significant achievements for AAM and the industry on the member-designated priority issues at the state, federal and international levels.
Congress passed the Drug Quality and Security Act to establish a nationwide, reliable system for tracking prescription medicine that further safeguards our nation’s prescription drug supply and protects patients.
In the states, we challenged legislation that would hinder access to biosimilars and interchangeable biosimilars. Bills were introduced in 19 states in 2013, blocked in 11, enacted with significant amendments in three states, and enacted with Amgen and Genentech-backed provisions intact in only one state (North Dakota). Also in 2013, the Supreme Court reaffirmed the constitutionality of patent settlements with consideration and preserved the unprecedented success of the current path for getting generics quickly to patients and consumers.
We posted record annual operating revenues of $12.6 million, record attendance of 677 at our Annual Meeting in Orlando, and a record attendance of 578 at our Fall Technical Conference. We also hired a total of six new colleagues across the Communications, Government Affairs and Science & Regulatory Affairs departments. And we moved into new office space that gives us more room to grow.
Read the highlights from 2013: